Principal Financial Group Inc Outlook Therapeutics, Inc. Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$0.22 - $0.66 $551 - $1,655	2,508 Added 14.9%	19,336 $7,000
Q3 2023 Nov 02, 2023	SELL	$0.2 - $1.78 $296 - $2,639	-1,483 Reduced 8.1%	16,828 $3,000
Q2 2023 Aug 07, 2023	BUY	$1.02 - $1.89 $1,400 - $2,594	1,373 Added 8.11%	18,311 $31,000
Q1 2023 May 09, 2023	BUY	$1.0 - $1.35 $2,681 - $3,619	2,681 Added 18.8%	16,938 $18,000
Q4 2022 Feb 09, 2023	SELL	$0.87 - $1.33 $2,883 - $4,407	-3,314 Reduced 18.86%	14,257 $15,000
Q3 2022 Nov 09, 2022	SELL	$1.02 - $1.26 $1,343 - $1,659	-1,317 Reduced 6.97%	17,571 $21,000
Q2 2022 Aug 10, 2022	SELL	$0.91 - $2.01 $19,711 - $43,538	-21,661 Reduced 53.42%	18,888 $19,000
Q1 2022 May 09, 2022	BUY	$1.22 - $2.03 $4,712 - $7,841	3,863 Added 10.53%	40,549 $72,000
Q4 2021 Feb 09, 2022	BUY	$1.27 - $2.23 $22,429 - $39,384	17,661 Added 92.83%	36,686 $50,000
Q3 2021 Nov 09, 2021	BUY	$2.12 - $2.76 $10,648 - $13,863	5,023 Added 35.87%	19,025 $41,000
Q2 2021 Aug 10, 2021	BUY	$1.78 - $2.76 $24,923 - $38,645	14,002 New	14,002 $34,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.